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Introduction
Polycystic ovary syndrome (PCOS) affects ß10% of women of reproductive age, constituting an endocrine disorder with serious reproductive and metabolic consequences. Obesity is present in ß80%, and insulin resistance ranges between 44 and 70% in these women, independent of body mass index (Barber et al. 2006) . Both obesity and insulin resistance aggravate the metabolic consequences of PCOS, leading to glucose intolerance, dyslipidaemia, chronic inflammation and hypertension. The pathophysiology of PCOS involves multiple factors, but an increased production of androgens plays a key role in the pathophysiology of PCOS (Azziz, 2003) . In this context, elevated androgen levels can lead to insulin resistance and compensatory hyperinsulinaemia, which further increase ovarian androgen production (Corbould, 2007) . Moreover, women with PCOS exhibit adipose tissue dysfunction characterized by enlarged adipocytes and reduced catecholamine-stimulated lipolysis, which could lead to insulin resistance and lower circulating concentrations of adiponectin (Faulds et al. 2003; Mannerås-Holm et al. 2011) . Women with PCOS also have high sympathetic nerve activity associated with hyperandrogenism (Sverrisdóttir et al. 2008) .
In general, diverse rat models have proved to be important tools in the search for the pathophysiological basis of PCOS. However, a low number of models mimic both the reproductive and the metabolic abnormalities observed in women with PCOS (Maliqueo et al. 2014) . In this regard, continuous administration of letrozole (200 μg day −1 ), an inhibitor of aromatase activity, to prepubertal rats results in a phenotype with striking similarities to human PCOS, with these animals exhibing abnormal gonadotrophin secretion, polycystic ovarian morphology, anovulation and elevated androgen concentrations (Maliqueo et al. 2013) . These rats also develop metabolic disturbances, including insulin resistance and enlarged adipocytes (Maliqueo et al. 2013) , which is most likely to be a result of androgen excess because PCOS models induced by dihydrotestosterone (DHT) develop a similar phenotype in rats and mice (Mannerås et al. 2007; van Houten et al. 2012) . Nonetheless, as letrozole inhibits the activity of P450 aromatase, the metabolic abnormalities could also be attributed to reduced oestrogen activity. In this regard, it has been reported that lower ovarian aromatase activity could be also present in women with PCOS, contributing to the abnormalities observed in these women (Chen et al. 2015; Dewailly et al. 2016) Ovariectomized female rats and aromatase and oestrogen receptor knockout mice display obesity, insulin resistance and dyslipidaemia (Heine et al. 2000; Jones et al. 2000; Song et al. 2005) . Furthermore, an imbalance in the synthesis of androgens and oestrogens contributes to an overactivation of the sympathetic nervous system, which is associated with increases in abdominal fat accumulation and insulin resistance (Dart et al. 2002; Nohara et al. 2013) .
Low-frequency electroacupuncture (EA) has wellcharacterized beneficial effects on reproductive functions because it induces ovulation and improves the circulating sex steroid profile and ovarian morphology in women with PCOS (Stener-Victorin et al. 2000; Johansson et al. 2013b) . Furthermore, in letrozole-induced PCOS rats, 5-6 weeks of low-frequency EA improves the gonadotrophin profile and ovarian adiponectin signalling (Maliqueo et al. 2015) . Also, in DHT-induced PCOS rats, EA for 4-5 weeks results in normalization of the expression of opioid receptors in the hypothalamic arcuate nucleus and an improvement in oestrous cyclicity (Feng et al. 2012) .
In comparison, the effects of EA on metabolic disorders in women with PCOS are controversial. In a DHT-induced rat model of PCOS, acupuncture improved insulin sensitivity by mobilizing glucose transporter 4 to the cell membrane in skeletal muscle and adipose tissue (Johansson et al. 2010 (Johansson et al. , 2013a . Moreover, it normalized the expression of genes encoding sympathetic markers in adipose tissue (Mannerås et al. 2009 ). In turn, low-frequency EA stimulated aromatase activity in the liver and subcutaneous abdominal adipose tissue and increased circulating estradiol concentrations in ovariectomized rats (Zhao et al. 2004 (Zhao et al. , 2005 .
In the present study, we tested the hypothesis that low-frequency EA treatment in letrozole-induced PCOS rats improves insulin sensitivity, promotes morphological and functional changes in skeletal muscle and adipose tissue and modulates the expression of genes related to insulin sensitivity, lipid metabolism and sympathetic activity in subcutaneous adipose tissue. Metabolic function was assessed by euglycaemic-hyperinsulinaemic clamp studies and analysis of the body composition, food intake and lipid profile. The effects of EA were compared with a non-selective β-blockade and with a low-dose of estradiol administrated in a cyclic way, mimicking the circulating estradiol concentrations reached during a normal oestrous cycle.
Methods
The study was conducted under the principles of the 'Guide to the Care and Use of Experimental Animals' (www.sjv.se) and approved by the animal Ethics Committee at the University of Gothenburg (no. 364-2011) .
Animals
Eight Wistar dams, each with 7-9 14-day-old female pups, were purchased from Charles River Laboratories (Munster, Germany). Pups were separated from their dams at 21 days of age, allocated randomly in the different experimental groups and housed 3-5 per cage. All animals were maintained under controlled conditions (21-22 C, 55-65% humidity and 12-h light/12-h dark cycle) with free access to standard rat chow (Harlan Teklad Global Diet, Harlan, Germany) and tap water.
Study procedure (Fig. 1) A PCOS phenotype was induced in 50 rats by S.C. implantation, under light general anaesthesia by inhalation of isoflurane (2% in 1:1 mixture of oxygen and air; Abbott Scandinavia AB, Solna, Sweden), of a 90 day continuous-release pellet (Innovative Research of America, Sarasota, FL, USA) containing 18.0 mg (daily dose, 200 μg) of letrozole (Novartis Pharma, Basel, Switzerland; Maliqueo et al. 2013) at 21 days of age. Twelve control rats received an identical pellet lacking the bioactive molecule, a so-called placebo pellet. All rats were weighed weekly from 21 days of age. After 5 weeks of letrozole exposure, five rats were excluded because they did not develop a typical PCOS phenotype as they had normal oestrous cyclicity and no changes in body weight, as previously described (Maliqueo et al. 2013) .
Six weeks after pellet implantation (63 days of age) letrozole-exposed rats received 5-6 weeks of the following: low-frequency EA (letrozole-EA, n = 9); a β-adrenergic blocker (letrozole-propranolol, n = 10); or estradiol every fourth day (letrozole-estradiol, n = 10). As the acupuncture treatment was performed in conscious rats, letrozole-exposed control rats were handled 5 days per week without needle insertion (n = 8) as a control for EA, or received sesame oil injections every fourth day (n = 8), as a control for injection of estradiol or propranolol. Given that there were no differences in the murinometric and metabolic variables between the letrozole handling and the letrozole injection control groups, the two groups were pooled (letrozole, n = 16). After 3-4 weeks of treatments, a locomotion test, body composition analysis and blood sampling were performed. The study was concluded after 11-12 weeks of pellet implantation. Rats were killed by decapitation under deep thiobutabarbital anaesthesia (Inactin; Sigma, St Louis, MO, USA).
Treatments
Low-frequency EA. Acupuncture was performed 5 days per week in conscious rats from Monday to Friday according to previous studies (Johansson et al. 2010; Maliqueo et al. 2015) . After induction of light general anaesthesia with isoflurane (2% in a 1:1 mixture of oxygen and air) for 2-3 min, two acupuncture needles (0.20 mm in diameter and 15 mm long; HEGU Svenska, Landsbro, Sweden) were placed bilaterally, 5-8 mm deep, in the rectus abdominis, and two needles, 5-10 mm deep, in each soleus and gastrocnemius hindlimb muscles. Then, rats were placed in a fabric harness and suspended above the table and needles stimulated with 2.0 Hz with 0.1 s, 80 Hz burst pulses using an electric stimulator (CEFAR ACU II; Cefar-Compex Scandinavia, Malmö, Sweden) for 15 min during week 1, 20 min during weeks 2 and 3, and thereafter 25 min. The intensity was adjusted between 0.6 and 1.4 mA. A group of letrozole-exposed (n = 8) and control (placebo) rats (n = 7) underwent the same handling procedure but without the needle insertion to control for environmental factors (Mannerås et al. 2009; Johansson et al. 2010; Maliqueo et al. 2015) . −1 (P0884; Sigma) dissolved in saline (Bonnet et al. 2006) . In order to mimic the circulating estradiol concentrations during the oestrous cycle, 2 μg of 17β-estradiol-3-benzoate (E8515; Sigma) dissolved in 100 μl of sesame oil was administrated every fourth day by S.C. injection (Asarian & Geary, 2002) . A group of letrozole-exposed and control rats received S.C. injections of 100 μl of sesame oil according to the regimen for cyclic estradiol. All the injections were made between 09.00 and 11.00 h.
Food intake
Food intake was calculated weekly as the difference between the amount of food given and the amount remaining after 1 week in each cage and was normalized to the average body weight of the rats in each cage.
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Locomotion test
Locomotor activity was assessed in non-habituated rats after 3 weeks of treatments using photocell animal motility meters consisting of eight soundproofed ventilated boxes (700 mm × 700 mm) equipped in the floor with eight-by-eight photobeams connected to a computer (Kungsbacka Mät-och Reglerteknik AB, Fjärås, Sweden). Briefly, one rat from each group was allocated randomly to one box, and the locomotor activity was assessed as the breaking of a sequence of beams, representing movement in a single direction. Between each measurement, the boxes were cleaned with 70% alcohol. Locomotor activity was defined as the accumulated number of new photocell beams interrupted (counts) during a 30 min period. The measurements were carried out between 11.00 and 13.00 h.
Blood sampling
After 4 weeks of treatments, blood samples, to assess insulin, adiponectin and lipid profile, were obtained after an overnight fast by tail-cut with a light restraint. Blood samples were obtained in the oestrus phase in cycling rats according to vaginal smear, and irrespective of cycle day in acyclic rats. 600 μl of these blood samples were immediately centrifuged at 10 000 g for 5 min, and plasma and serum were stored at −80°C.
Body composition
Body fat, lean body mass and bone mineral content (BMC) were determined in each rat by dual-energy X-ray absorptiometry after 4 weeks of treatments as described (Maliqueo et al. 2013) . Rats were anaesthetized by inhalation of isoflurane (2% in 1:1 mixture of oxygen and air; Abbott Scandinavia AB) during scanning.
Euglycaemic-hyperinsulinaemic clamp
In rats with evidence of oestrous cycle changes, evaluated by vaginal smear during 10 consecutive days, insulin sensitivity was assessed during the oestrus phase by euglycaemic-hyperinsulinaemic clamp after 5-6 weeks to induce a polycystic ovary syndrome (PCOS) phenotype, whereas control rats received an identical pellet lacking the bioactive molecule (placebo). Six weeks after pellet implantation, the letrozole-exposed rats received 5-6 weeks of low-frequency EA (letrozole-EA), β-adrenergic blocker (letrozole-propranolol) or estradiol every fourth day (letrozole-estradiol). Letrozole-exposed control rats were either handled 5 days per week without needle insertion or received sesame oil injections every fourth day. After 3-4 weeks of treatment, a locomotion test, body composition analysis [dual-energy X-ray absorptiometry (DEXA)] and blood sampling were performed. Insulin sensitivity and tissue glucose uptake were evaluated by euglycaemic-hyperinsulinaemic clamp.
of treatments (11-12 weeks after pellet implantation). Briefly, non-fasted rats were anaesthetized by I.P. injection of 160 mg kg −1 thiobutabarbital sodium (Inactin; Sigma). Cannulae were inserted into the left carotid artery for blood sampling and into the right jugular vein for glucose and insulin infusions. Respiration was maintained by tracheotomy. Insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) diluted in 10 ml of saline plus 0.2 ml of albumin was infused at 24, 16 and 12 mU min
for minutes 1, 2 and 3, respectively, followed by 8 mU min −1 kg −1 for the rest of the clamp. Plasma glucose was analysed every 5 min with a OneTouch Ultra 2 Meter (LifeScan, Milpitas, CA, USA) and maintained at 6.0 mmol l −1 by administration of 20% glucose in saline. A steady state was reached after 45-60 min and maintained for 20 min. The mean glucose infusion rate (GIR) at the steady state was normalized to body weight.
After the steady state was reached, a bolus of
3 H]DG) (NET549005MC; PerkinElmer, Boston, MA, USA) was injected into the venous cannula, and rats were kept at a steady state for 45 min. 50 μl of blood was collected into heparinized tubes at 2, 5, 10, 15, 20, 30 and 45 min after bolus injection for estimation of plasma tracer concentration. After the clamp, rats were decapitated, and hindlimb muscles [extensor digitorum longus (EDL), tibialis anterior and soleus] and retroperitoneal, parametrial, mesenteric and inguinal fat depots were rapidly dissected and weighed. Samples of muscle (soleus and EDL) and fat (inguinal and mesenteric) were frozen in liquid nitrogen for measurement of tissue glucose uptake. Messenger RNA expression was analysed in the inguinal fat depot.
Determination of tissue-specific glucose uptake
Fifty microlitre plasma samples for determination of tracer concentration were deproteinized into 1 ml of 2.75% ZnSO 4 and 350 μl saturated BaOH. The samples were then centrifuged at 1500 g for 10 min, and 500 μl of the supernatant was added to 3 ml scintillation fluid and radioactivity determined (Wallac 1409 counter; Wallac OY, Turku, Finland). Total tissue 3 H activities were determined in ß50 mg of tissue using a Packard System 387 Automated Sample Preparation Unit (Packard Instrument Co., Inc., Meriden, CT, USA), which completely oxidizes the sample and separates [ 3 H]H 2 O into scintillation vials for counting (Wallac 1409 counter). Tissue-specific glucose uptake was calculated in each tissue considering the plasma glucose concentration at steady state, tissue accumulation of ([2-3 H]DG) per unit mass at 45 min and the plasma time course of ([2-3 H]DG) from 2 to 45 min after tracer injection, as previously described (Kraegen et al. 1985) .
Computerized determination of adipocyte size
Adipocytes from the inguinal and mesenteric depots were isolated, and the mean diameter was determined by computerized image analysis using Leica software (Leica QWin V3; Leica Microsystems, Wetzlar, Germany), as previously described (Maliqueo et al. 2013) . Uniform microspheres 98 μm in diameter (Dynal; Invitrogen, Oslo, Norway) served as a reference.
Analytical methods
Adiponectin was assayed with a rat total adiponectin enzyme-linked immunosorbent assay (ELISA) kit (Quantikine, RRP300; R&D Systems, Abingdon, UK). Rat insulin was determined with an ultrasensitive ELISA kit (10-1251-01; Mercodia, Uppsala, Sweden). Human insulin given during the clamp was measured with an ELISA kit (10-1113-01; Mercodia). The intra-and interassay coefficients of variation was 3.3% and sensitivity were, respectively, 7.8% and 0.02 ng ml −1 for adiponectin and 2.0%, 4.2% and 20.0 pg ml −1 for rat insulin. Lipid profiles were determined enzymatically with a Konelab 20 autoanalyser (Thermo Fisher Scientific). The interassay coefficients of variation were <3%.
Total RNA isolation and quantitative real-time PCR
Total RNA was isolated from inguinal fat tissue with commercial kits (74804; Qiagen, Hilden, Germany). The RNA quality was evaluated with an Experion electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA). First-strand cDNA was prepared from 1 μg of total RNA with Superscript VILO (Life Technologies, Paisley, UK) following the manufacturer's protocol.
For real-time RT-PCR, 500 ng of cDNA was analysed with an ABI Prism 7900HT Sequence Detection System, ABI Prism 7900HT SDS Software 2.4 (Applied Biosystems, Carlsbad, CA, USA), and custom TaqMan low-density array (Applied Biosystems) for 48 genes (Table 1) . Five putative reference genes were included [18S ribosomal RNA (18S), β-actin (Actb), glyceraldehyde-3-phosphate dehydrogenase (Gapdh), peptidylprolyl isomerase A (Ppia) and hypoxanthine guanine phosphoribosyl transferase (Hprt)] and 43 target genes related to steroidogenesis, insulin resistance, adipokines and sympathetic/adrenergic activation. Thermal cycling conditions were 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C.
The expression stability of reference genes was calculated with the NormFinder algorithm (Andersen et al. 2004) . Variability was lowest with the combination of Hprt1 and Ppia for inguinal fat. Gene expression values were calculated with the 2 − C t method (Livak & Schmittgen, 2001 ). 
Statistical analyses
Statistical analyses were performed with SPSS (version 21.0; SPSS, Chicago, IL, USA) and GraphPad Prism (version 5.03; GraphPad Software, La Jolla, CA, USA).
The differences between control (placebo), letrozole, letrozole-EA, letrozole-propranolol and letrozoleestradiol were calculated using the Kruskal-Wallis test followed by the Mann-Whitney U test. Body weight change and food intake were analysed by repeatedmeasures ANOVA. Data are expressed as means ± SD. A value of P < 0.05 was considered significant.
Results
Weight development and food intake
Three weeks after pellet implantation and onwards, letrozole-exposed rats weighed more than control rats [F(4, 40) = 28.04, P < 0.001; Fig. 2A ]. The weight gain from the start to the end of the treatment period with low-frequency EA, propranolol or estradiol did not differ in any of the letrozole-exposed rats [F(3, 12) = 2.27, P = 0.094; Fig. 2A ]. Food intake did not differ between the control and letrozole-exposed rats or in any of the treated groups [F(4, 36) = 1.0, P = 0.467; Fig. 2B ].
Locomotor activity
Rats exposed to letrozole exhibited lower locomotor activity than control animals (P = 0.003; Fig. 3 ). On the contrary, treatment with estradiol increased the activity in comparison with rats treated with letrozole alone (P = 0.004; Fig. 3) , with no change observed in rats treated with low-frequency EA or propranolol (Fig. 3) .
Body composition
Dual-energy X-ray absorptiometry. Letrozole-exposed rats were heavier than control animals and had a higher fat content (56.3 ± 12.5 versus 32.9 ± 7.1 g, P < 0.001), lean body mass (287.4 ± 27.2 versus 209.0 ± 17.3 g, P < 0.001) and BMC (9.1 ± 1.4 versus 7.1 ± 0.8 g, P < 0.001). In relation to BW, fat content was higher (P = 0.017), whereas lean body mass (P = 0.013) 
. Body weight (A) and food intake (B) from pellet implantation (21 days of age) to 91 days of age
A, body weight from pellet implantation (21 days of age) to 91 days of age in control (placebo; n = 12), letrozole (n = 16), letrozole-EA (n = 9), letrozole-propranolol (n = 10) and letrozole-estradiol (n = 10) groups. B, food intake per cage from pellet implantation (21 days of age) to 91 days of age in control (placebo; n = 3), letrozole (n = 6), letrozole-EA (n = 3), letrozole-propranolol (n = 3) and letrozole-estradiol (n = 3) groups. Values are means ± SD. * * * P < 0.001 versus letrozole group.
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and BMC (P < 0.001) were lower in letrozole-exposed rats than in control rats ( Fig. 4A-C) . None of the treatments affected the body composition or BMC.
Muscle (table 2) . The EDL, tibialis anterior and soleus weighed more in letrozole-exposed rats than in control animals. In relation to BW, soleus weighed less in letrozole-exposed rats than in control animals (P = 0.001). Muscle weights were similar in letrozole-exposed rats compared with letrozole-exposed rats treated with low-frequency EA, propranolol or estradiol.
Fat depots (table 2).
The inguinal (P < 0.001), parametrial (P = 0.001) and mesenteric fat depots (P = 0.023) weighed more in letrozole-exposed rats than in control animals. However, no difference was observed in relation to BW. No difference in any fat depot was observed in letrozole-exposed rats treated with low-frequency EA, estradiol or propranolol compared with rats treated with letrozole alone.
Adipocyte size. Adipocytes in inguinal (P = 0.008) and mesenteric fat depots (P = 0.046) were larger in letrozole-exposed rats than in control animals ( Fig. 5A and B). Low-frequency EA, estradiol or propranolol did not affect adipocyte size in any investigated fat depot ( Fig. 5A and B).
Insulin sensitivity
The mean GIR was lower in letrozole-exposed rats than in control animals (P < 0.001; Fig. 6 ). The GIR did not differ between letrozole-EA rats and letrozole-exposed rats (25.6 ± 5.9 versus 21.6 ± 2.9 mg kg −1 min −1 ; P = 0.153). Values were normalized to body weight and are shown as means + SD. * * P < 0.01 and * P < 0.05 versus letrozole group. Acupuncture in rat model of polycystic ovary syndrome However, we identified three non-responding rats, which were below to the cut-off value of 20.96 mg kg
(mean − 2SD of the control; Fig. 6, box) . When the non-responders were excluded, the GIR was higher in letrozole-EA rats than in rats treated with letrozole alone (29.2 ± 4.1 versus 21.6 ± 2.9 mg kg −1 min −1 ; P = 0.004). Cyclic estradiol treatment resulted in higher GIR than in rats treated with letrozole alone (P = 0.026), whereas the GIR after propranolol treatment tended to be higher than that of rats treated with letrozole alone (P = 0.052; Fig. 6 ).
Tissue-specific glucose uptake
The tissue-specific glucose uptake in EDL (P = 0.037) and mesenteric fat (P = 0.023) was lower in letrozole-exposed rats than in control rats (Table 3) . Treatment with low-frequency EA, cyclic estradiol or propranolol did not affect the tissue-specific glucose uptake values in any of the tissues analysed (Table 3) .
Circulating levels of insulin, adiponectin and lipid profile
Rats exposed to letrozole had higher serum insulin (P < 0.009) and triglyceride (P < 0.001) and lower adiponectin (P < 0.003) concentrations than control rats (Table 4) . Treatment with low-frequency EA (P = 0.032), cyclic estradiol (P = 0.031) or propranolol (P = 0.035) increased the serum concentration of low-density lipoprotein (LDL)-cholesterol compared with rats treated with letrozole alone, with no change in insulin or adiponectin concentrations (Table 4) . Moreover, rats treated with letrozole-estradiol had lower triglyceride concentrations compared with rats treated with letrozole alone (P = 0.023; Table 4 ). Of interest, in those rats exposed to letrozole that responded to low-frequency EA, serum triglyceride concentrations tended to be lower in comparison to rats treated with letrozole alone (0.88 ± 0.25 versus 1.17 ± 0.31 nmol l −1 , P = 0.055).
Gene expression
Inguinal mRNA expression of Adipor1, Adrb2, Ar, Ccl2, Esr2, Foxo3, Gsk3b, Hmox1, Insr, Lpl, Pdk4, Pik3cb, Prkaa2 and Srd5a1 was higher and expression of Mtor, Ngfr and Pparg was lower in letrozole-exposed rats than in control rats (Fig. 7) . Cyclic estradiol treatment decreased mRNA expression levels of Adipor1, Adrb2, Ar, Foxo3, Gsk3b, Insr, Pdk4, Pik3cb and Srd5a1 and increased Ccl2, Mtor, Ngfr and Pparg compared with rats treated with letrozole alone (Fig. 7) . In contrast, Prkaa2 was higher and Ccl2 and Foxo3 tended to be higher (P = 0.052) in the letrozole-propranolol group compared with the letrozole-only group. No effects of EA were observed (Fig. 7) .
Discussion
This study shows that low-frequency EA does not essentially affect metabolic function in a PCOS model induced by the inhibition of P450 aromatase. In contrast, the administration of estradiol in a way that resembled a normal oestrous cycle restored insulin sensitivity, circulating triglycerides and the gene expression of adipokines and a number of genes involved in steroid action, insulin resistance and sympathetic/ adrenergic activation in inguinal fat, indicating that these parameters are more related to decreased oestrogen action rather than hyperandrogenism. Importantly, we confirm and expand our previous knowledge about metabolic disturbances in the letrozole-induced rat model of PCOS.
Body weight, body composition and locomotor activity
Androgen excess has been implicated in the accumulation of body fat, mainly in the abdominal fat depot, both in female rats exposed to DHT and in women with PCOS Mannerås et al. 2007; Borruel et al. 2013 ), which seems not be related to an increase in food intake. In this regard, we have described that rats in the letrozole-induced PCOS model show elevated circulating androgen concentrations but low or normal estradiol concentrations (Maliqueo et al. 2013 (Maliqueo et al. , 2015 . Moreover, letrozole reduced the lean mass and BMC, which is in agreement with observations in aromatase knockout mice (Jones et al. 2001; Oz et al. 2001) . In contrast to our data, aromatase knockout mice display reduced fat mass and restoration of the BMC after 21 days of continuous replacement with 50 μg of estradiol Misso et al. 2003) . However, we cannot exclude the possibility that supraphysiological concentrations of estradiol are needed to revert the effect of androgen on adipose tissue and BMC. Although letrozole-exposed rats treated with estradiol increased their locomotor activity, no reduction in body weight was observed, pointing towards the fact that the accumulation of adipose tissue in rats exposed to letrozole is a consequence of the direct effect of androgens on adipose cells. The locomotor activity is most likely to be related to low oestrogen concentrations rather than excessive androgen secretion, as reduced locomotor activity seen in ovariectomized rats is reversed by oestrogen replacement (Blizard et al. 1975) . Also, rats with DHT-induced PCOS do not exhibit changes in locomotor activity, further indicating an important role of oestrogens rather than androgens in locomotor activity (Sellix et al. 2013) .
Insulin sensitivity, adipocyte size and lipid profile
The decreased insulin sensitivity in the letrozole-induced PCOS model was related to a decreased glucose uptake in EDL muscle and mesenteric fat. Testosterone treatment in female rats has been shown to increase the density of white muscle fibres in EDL and soleus muscle, decreasing the muscle insulin sensitivity (Holmäng et al. 1990) . Glucose uptake and adiponectin secretion are higher in visceral fat compared with subcutaneous fat mass (Perrini et al. 2008) . Therefore, metabolic and functional alterations in visceral fat related to enlarged adipocytes can also contribute to the decreased insulin sensitivity in the letrozole-induced PCOS model. In this regard, large adipocytes have a reduced capacity for insulin-stimulated GLUT4 translocation, which suggests reduced insulin responsiveness and altered secretion of adipokines (Franck et al. 2007; Skurk et al. 2007) . Moreover, the elevated triglyceride concentrations observed in rats with letrozole-induced PCOS can be the result of dysfunctional visceral adipocytes and altered hepatic lipid metabolism (Veilleux et al. 2011) . Adipose tissue hypertrophy leads to increased lipolysis, which in turn increases circulating free fatty acid concentrations and reduces the insulin sensitivity in skeletal muscle and liver (Samuel et al. 2010) . In women with PCOS, visceral fat accumulation is correlated with insulin resistance and dyslipidaemia, including elevated concentrations of triglycerides (Lord et al. 2006) . We cannot exclude the possibility that letrozole affected the function of brown adipose tissue, inducing metabolic abnormalities related to PCOS. In this regard, it was recently demonstrated that brown adipose tissue activity is decreased in PCOS induced by prenatal androgenization, and brown adipose tissue transplantation reverted the metabolic abnormalities, which was mediated by an increase of circulating adiponectin concentrations (Yuan et al. 2016) We demonstrate that cyclic estradiol treatment and blockade of β-adrenergic receptors increase whole-body insulin sensitivity without changing glucose uptake in muscle or fat. Therefore, these treatments most probably improve insulin sensitivity by regulating hepatic insulin sensitivity rather than by altering peripheral glucose uptake. Support for these findings comes from oestrogen receptor α knockout mice, which exhibit hepatic insulin resistance with a modest decrease in insulin-stimulated glucose uptake in soleus and EDL muscles (Bryzgalova et al. 2006) . Moreover, the stimulation of β-adrenergic receptors with isoprenaline increases hepatic glucose production, leading to insulin resistance (Muscogiuri M. Maliqueo and others et al. 2011) . In the hepatic insulin-resistant state, hepatic very low-density lipoprotein output is increased, leading to increased serum triglycerides (Choi & Ginsberg, 2011) . Therefore, the normalization of circulating triglyceride concentrations induced by estradiol and the increase of circulating LDL concentrations induced by estradiol and adrenergic receptor blockade support the concept that these treatments act through the regulation of hepatic insulin sensitivity. Low-frequency EA increased circulating LDL-cholesterol concentrations, similar to propranolol and estradiol, which could be a conflicting result because LDL-cholesterol is associated with a higher risk for cardiovascular diseases; however, in contrast to humans, in rats high-density lipoprotein carries more cholesterol than LDL (Harris, 1997) . In this regard, EA seems to modulate the hepatic lipid metabolism and lipid profile (Li & Zhang, 2007; Lin et al. 2009 ). Although it was not clear whether low-frequency EA improves insulin sensitivity in the letrozole-induced PCOS model, we observed a subgroup of rats that responded to low-frequency EA by normalization of insulin sensitivity, with a strong tendency to improvement in the serum concentration of triglycerides. Previously, we reported the reproductive features of the present study (Maliqueo et al. 2015) . Interestingly, those rats exposed to letrozole that did not respond to low-frequency EA tended to have higher circulating testosterone concentrations compared with rats responding to the treatment (data not shown).
Gene expression in subcutaneous adipose tissue
Several genes involved in regulation of whole-body insulin sensitivity and lipogenesis were upregulated in subcutaneous fat, including Adipor1, Gsk3b, Insr, mTOR, Pdk4, Pik3cb, Prkaa2, Lpl and Hmox,  in the letrozole-induced PCOS model. Changes in gene expression may be a compensatory mechanism for the decreased insulin sensitivity and elevated triglyceride concentrations, because subcutaneous fat might buffer the uptake of fatty acids and thereby prevent exposure of other insulin-sensitive tissues to the detrimental effects (Manolopoulos et al. 2010) . In this regard, the glucose uptake was maintained in subcutaneous fat in letrozole-exposed rats.
In contrast, the downregulation of Pparg suggests an impaired adipocyte differentiation in rats exposed to letrozole. PPARγ, encoded by the Pparg gene, is a central regulator of adipogenesis, and thus of the insulin sensitivity (McLaughlin et al. 2007) . Remarkably, in subcutaneous fat from women with PCOS a lower expression of PPARG has been observed, suggesting impaired adipogenesis in these women (Kokosar et al. 2016) . On the contrary, the upregulation of Foxo3a, a transcription factor activated by oxidative stress, and oestrogen receptor β (Esr2) negatively regulate the expression of Pparg (Luo et al. 2008) . Interestingly, sheep exposed prenatally to testosterone exhibit an increase in the expression of molecules related to insulin signalling, such as IRS-2, PI3K, mTOR and Akt, although PPARγ was upregulated, suggesting an increase in the insulin sensitivity in adipose tissue (Nada et al. 2010) . Subcutaneous adipose tissue from PCOS-like female rhesus macaques and human multipotent adipose stem cells treated with androgen exhibit an altered differentiation of adipocyte precursors into adipocytes (Chazenbalk et al. 2013; Keller et al. 2014) . Interestingly, letrozole exposure increases the gene expression of Ar and Srd5a1, which could potentiate the intra-tissue androgen action. We also observed a dysregulation of Adrb2 (β 2 -adrenergic receptor) expression, which could be related to an increase in the sympathetic activity. However, a compensatory mechanism could be established because Ngfr, which encodes nerve growth factor receptor, was downregulated. Interestingly, the normalization of gene expression (i.e. Adipor1, Gsk3b, Insr, Lpl, mTOR, Pdk and Pik3cb) in inguinal fat by cyclic estradiol treatment may reflect the improvement in whole-body insulin sensitivity and lipid profile. Likewise, Pparg and Foxo3a expressions were restored, suggesting an improvement in adipogenesis in the presence of circulating estradiol concentrations mimicking the oestrous cycle. Moreover, cyclic estradiol normalized the expression of Ar and Srd5a1, probably leading to a reduction of the androgen action in this tissue.
Therefore, in the letrozole-induced PCOS model, the low oestrogen activity may explain the abnormal gene expression in subcutaneous adipose tissue along with an intensified intra-tissue androgen activity. Blocking β-adrenoreceptors did not reverse the expression of genes associated with insulin sensitivity, adipogenesis or steroid action. This suggests that the β-adrenergic pathway is not associated with impairments in subcutaneous adipose tissue, and this may also explain the lack of activity of low-frequency EA.
In conclusion, low-frequency EA during 5-6 weeks increased LDL-cholesterol and the insulin sensitivity in a subset of responding rats exposed to letrozole, which may reflect the improvement of estradiol action or β-adrenergic modulation of hepatic insulin sensitivity. In turn, cyclic estradiol treatment had a significant impact on insulin sensitivity and modulated gene expression in the inguinal fat depot, indicating that the low oestrogen action contributes to the metabolic phenotype of the letrozole-induced PCOS model.
